Report overview
Report Overview
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
The global Pegfilgrastim Biosimilar market size was estimated at USD 1522 million in 2023 and is projected to reach USD 2751.41 million by 2032, exhibiting a CAGR of 6.80% during the forecast period.
North America Pegfilgrastim Biosimilar market size was estimated at USD 444.17 million in 2023, at a CAGR of 5.83% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Pegfilgrastim Biosimilar market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pegfilgrastim Biosimilar Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Pegfilgrastim Biosimilar market in any manner.
Global Pegfilgrastim Biosimilar Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy
